» Articles » PMID: 24072210

Longitudinal Assessment in COPD Patients: Multidimensional Variability and Outcomes

Overview
Journal Eur Respir J
Specialty Pulmonary Medicine
Date 2013 Sep 28
PMID 24072210
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

The value and timing of multidimensional assessments in chronic obstructive pulmonary disease (COPD) remains unclear because there is little information about their variability and relationship to outcome. The aim of this study was to determine the progression of COPD using clinical and spirometric variability over time with mortality as the outcome. We determined the annual intra-individual variability of forced expiratory volume in 1 s (FEV1) and BODE (body mass index, airflow obstruction, dyspnoea, exercise capacity) index in 403 patients with at least five measurements. The pattern was defined as "stable" if the annual change remained constant in ≥66% of the observations and "unstable" if it did not meet that threshold. We explored the minimum number of yearly observations that related to mortality in the 704 patients of the cohort. The "unstable" pattern of FEV1 was seen in 53% and 40% of patients using a threshold of 40 mL·year(-1) and 100 mL·year(-1), respectively. There was a slightly more "stable" pattern in the BODE index (62% for 1 point). A profile associated with mortality was defined by a baseline measurement followed by annual measurements for 2 years of the BODE index, but not its individual components, including FEV1 (p<0.001). Progression of COPD measured using FEV1 is inconsistent and relates poorly to outcome. Monitoring the more stable BODE index better assesses disease progression.

Citing Articles

From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.

Divo M, Liu C, Polverino F, Castaldi P, Celli B, Tesfaigzi Y Eur Respir J. 2023; 62(3).

PMID: 37678951 PMC: 10533946. DOI: 10.1183/13993003.00806-2023.


COPD profiles and treatable traits using minimal resources: identification, decision tree and stability over time.

Marques A, Souto-Miranda S, Machado A, Oliveira A, Jacome C, Cruz J Respir Res. 2022; 23(1):30.

PMID: 35164762 PMC: 8842856. DOI: 10.1186/s12931-022-01954-6.


[Comparison of different evaluation systems for assessing disease severity and treatment efficacy in patients with chronic obstructive pulmonary disease].

Tan M, Jian W, Liang Q, Li S, Cui H Nan Fang Yi Ke Da Xue Xue Bao. 2021; 41(7):1119-1124.

PMID: 34308866 PMC: 8329678. DOI: 10.12122/j.issn.1673-4254.2021.07.23.


When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment.

Cheng W, Wu B, Liao W, Chen C, Chen W, Hsia T Int J Chron Obstruct Pulmon Dis. 2020; 15:3375-3384.

PMID: 33376318 PMC: 7764554. DOI: 10.2147/COPD.S279482.


Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.

Celli B, Locantore N, Yates J, Bakke P, Calverley P, Crim C Eur Respir J. 2020; 57(3).

PMID: 33303557 PMC: 7991608. DOI: 10.1183/13993003.01339-2020.